Third application for Orion’s prostate cancer drug submitted by partner Bayer

Natalia Elliot | September 23, 2024 | News story | |  Bayer, Cancer, Oncology, orion, prostate cancer 

Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, darolutamide, in the US.

Bayer has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for darolutamide, an oral androgen receptor blocker, to be in combination with standard hormonal treatment androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The application is supported by the results from the phase 3 ARANOTE trial.

Liisa Hurme, CEO of Orion, commented: “This is a historic achievement for Orion and yet another proof of the high quality of our research and development work that has been going on for years. With the current level of performance continuing, the future looks bright for darolutamide. Both our clinical development pipeline and our research pipeline have also strengthened recently. With this development, we are improving the chances that we will be able to meet the diverse needs of patients and bring new innovative medicines to the market in the future.”

Advertisement

James Spargo


Related Content

Evotec and Bayer announce new kidney disease study

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

nerve-cell-2213009_960_720

Central nervous system cancer metastases – the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design

BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …

The Gateway to Local Adoption Series

Latest content